Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRMA Dermata Therapeutics	$5.64 -4.7%	$6.68	$5.22 ▼ $24.90	$3.84M	0.56	75,365 shs	35,309 shs
EVAX Evaxion A/S	$3.04 -5.6%	$2.64	$1.20 ▼ $17.75	$4.26M	0.13	976,930 shs	106,931 shs
REVB Revelation Biosciences	$2.53 -6.6%	$2.57	$2.11 ▼ $168.00	$4.61M	-0.06	220,981 shs	161,240 shs
SKVI Skinvisible	$0.17 +2.4%	$0.21	$0.14 ▼ $0.85	$891K	2.05	5,237 shs	4,000 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRMA Dermata Therapeutics	-2.84%	-5.68%	-14.18%	-28.09%	-70.36%
EVAX Evaxion A/S	+11.81%	+16.25%	+22.43%	+84.00%	-79.96%
REVB Revelation Biosciences	+5.04%	+13.87%	-8.14%	-64.01%	-93.44%
SKVI Skinvisible	0.00%	-14.85%	-19.45%	-23.50%	-58.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRMA Dermata Therapeutics	3.3473 of 5 stars	3.5	5.0	0.0	0.0	3.6	0.8	0.6
EVAX Evaxion A/S	1.869 of 5 stars	3.5	2.0	0.0	0.0	1.6	1.7	0.0
REVB Revelation Biosciences	0.5833 of 5 stars	0.0	2.0	0.0	0.0	2.5	0.0	1.3
SKVI Skinvisible	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRMA Dermata Therapeutics	3.00	Buy	$30.00	431.91% Upside
EVAX Evaxion A/S	3.00	Buy	$10.00	228.95% Upside
REVB Revelation Biosciences	0.00	N/A	N/A	N/A
SKVI Skinvisible	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SKVI, REVB, DRMA, and EVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $30.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$6.20 per share	N/A
EVAX Evaxion A/S	$3.34M	1.27	N/A	N/A	($1.18) per share	-2.58
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$9.02 per share	N/A
SKVI Skinvisible	$20K	44.55	N/A	N/A	($1.86) per share	-0.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRMA Dermata Therapeutics	-$12.29M	-$16.41	N/A	∞	N/A	N/A	-214.98%	-153.76%	N/A
EVAX Evaxion A/S	-$10.57M	-$1.32	N/A	N/A	N/A	-316.03%	-409.87%	-67.90%	10/30/2025 (Estimated)
REVB Revelation Biosciences	-$15.04M	-$68.61	N/A	N/A	N/A	N/A	-240.27%	-148.95%	N/A
SKVI Skinvisible	-$570K	-$0.08	N/A	∞	N/A	-2,635.00%	N/A	-351.46%	N/A

Latest SKVI, REVB, DRMA, and EVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EVAX Evaxion A/S	-$0.50	-$0.76	-$0.26	-$0.76	N/A	$0.04 million
8/13/2025	Q2 2025	DRMA Dermata Therapeutics	-$2.90	-$1.66	+$1.24	-$1.66	N/A	N/A
8/13/2025	Q2 2025	SKVI Skinvisible	N/A	-$0.05	N/A	-$0.05	N/A	N/A
8/7/2025	Q2 2025	REVB Revelation Biosciences	-$4.46	-$7.01	-$2.55	-$7.01	N/A	N/A
5/27/2025	Q1 2025	EVAX Evaxion A/S	-$0.65	-$0.29	+$0.36	-$0.29	$0.06 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A
SKVI Skinvisible	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRMA Dermata Therapeutics	N/A	6.47	6.47
EVAX Evaxion A/S	N/A	2.01	2.01
REVB Revelation Biosciences	N/A	3.42	3.42
SKVI Skinvisible	N/A	0.01	0.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRMA Dermata Therapeutics	8.67%
EVAX Evaxion A/S	11.04%
REVB Revelation Biosciences	12.80%
SKVI Skinvisible	N/A

Insider Ownership

Company	Insider Ownership
DRMA Dermata Therapeutics	18.50%
EVAX Evaxion A/S	41.64%
REVB Revelation Biosciences	2.30%
SKVI Skinvisible	53.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRMA Dermata Therapeutics	8	680,000	556,000	Not Optionable
EVAX Evaxion A/S	60	1.40 million	819,000	No Data
REVB Revelation Biosciences	10	1.70 million	1.66 million	Not Optionable
SKVI Skinvisible	2	5.40 million	2.54 million	Not Optionable

SKVI, REVB, DRMA, and EVAX Headlines

Recent News About These Companies

Skinvisible Delays 10-K Filing Due to Compilation Issues

March 31, 2025 | tipranks.com

Skinvisible, Inc.: Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

January 23, 2025 | finanznachrichten.de

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

January 23, 2025 | accessnewswire.comA

Skinvisible, Inc. (SKVI)

November 16, 2024 | finance.yahoo.com

Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development

October 3, 2024 | accesswire.comA

Promising Data on Transdermal Obesity Formulations Announced by Skinvisible

July 11, 2024 | accesswire.comA

Skinvisible Expands Obesity Patent Application for Transdermal Delivery

June 24, 2024 | accesswire.comA

Skinvisible, Inc.: Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

May 29, 2024 | finanznachrichten.de

Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

May 29, 2024 | finance.yahoo.com

ZHUD Zhuding International Limited

May 15, 2024 | seekingalpha.com

Skinvisible, Inc.: Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

February 14, 2024 | finanznachrichten.de

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

February 14, 2024 | finance.yahoo.com

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

February 14, 2024 | accesswire.comA

Free weights 362X germier than a toilet seat

May 26, 2023 | mensjournal.comM

Skinvisible, Inc. (SKVI) Stock Historical Prices & Data - Yahoo Finance

March 2, 2023 | finance.yahoo.com

SKVI.PK - Skinvisible Inc | Stock Price & Latest News | Reuters

September 8, 2022 | reuters.com

Skinvisible Inc: Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug

June 6, 2022 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKVI, REVB, DRMA, and EVAX Company Descriptions

Dermata Therapeutics NASDAQ:DRMA

$5.64 -0.28 (-4.73%)

Closing price 03:57 PM Eastern

Extended Trading

$5.64 0.00 (0.00%)

As of 06:18 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Evaxion A/S NASDAQ:EVAX

$3.04 -0.18 (-5.59%)

Closing price 04:00 PM Eastern

Extended Trading

$3.07 +0.03 (+0.99%)

As of 06:40 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Revelation Biosciences NASDAQ:REVB

$2.53 -0.18 (-6.64%)

Closing price 04:00 PM Eastern

Extended Trading

$2.54 +0.02 (+0.59%)

As of 06:52 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Skinvisible OTCMKTS:SKVI

$0.17 +0.00 (+2.42%)

As of 10:25 AM Eastern

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time